You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Systemic Therapy for Metastatic Urothelial Cancer: An Endorsement of a Portion of the European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancer

ID: GL END 3-24 aoû 2022
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
S. Hotte, J. Brown, C. Canil, A. Lalani, S. Sridhar, the Systemic Therapy for Metastatic Urothelial Cancer Guideline Development Group

Guideline Objective:

The objectives of this guideline are to assess the optimal systemic therapy for metastatic urothelial cancer. Our recommendations are based on a portion of the 2021 European Association of Urology (EAU) guideline on Muscle-Invasive and Metastatic Bladder Cancer https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/.

Patient Population:

The target population is patients with metastatic urothelial cancer.

Intended Guideline Users:

The intended users of this guideline are clinicians involved in the care of patients with metastatic urothelial cancer.

pdf download Full Report (PDF) (483.06 Ko)